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Recent studies suggest that the sterol metabolic
network participates in the interferon (IFN) antiviral
response. However, the molecular mechanisms link-
ing IFN with the sterol network and the identity of
sterol mediators remain unknown. Here we report
a cellular antiviral role for macrophage production
of 25-hydroxycholesterol (cholest-5-en-3b,25-diol,
25HC) as a component of the sterol metabolic
network linked to the IFN response via Stat1. By
utilizing quantitative metabolome profiling of all
naturally occurring oxysterols upon infection or
IFN-stimulation, we reveal 25HC as the only macro-
phage-synthesized and -secreted oxysterol. We
show that 25HC can act at multiple levels as a potent
paracrine inhibitor of viral infection for a broad range
of viruses. We also demonstrate, using transcrip-
tional regulatory-network analyses, genetic interven-
tions and chromatin immunoprecipitation experi-
ments that Stat1 directly coupled Ch25h regulation
to IFN in macrophages. Our studies describe a phys-
iological role for 25HC as a sterol-lipid effector of an
innate immune pathway.
INTRODUCTION
Metabolism and innate immunity are increasingly viewed as
being connected and pathway mechanisms exist for sharing
resources and cross-regulation (Im et al., 2011).
Cholesterol is a vital component of cellular membranes and is
critical to a broad range of cellular functions. As a result, elabo-106 Immunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc.rate homeostatic mechanisms have evolved to control sterol
metabolism at multiple levels within and outside the cell (Horton
et al., 2002). Importantly, several of these mechanisms involve
25-hydroxycholesterol (25HC). The synthesis of transcripts en-
coding virtually all enzymes of the sterol biosynthesis pathway
is regulated by the transcription factor Srebp2. Moreover, the
Srebp2 processing pathway, responsible for endoplasmic retic-
ulum retention of the protein or proteolytic activation and trans-
location to the nucleus, is subject to inhibition by 25HC (Gong
et al., 2006; Radhakrishnan et al., 2007; Yabe et al., 2002). In
the mevalonate arm of the pathway, HMGCR serves as a key
control point (Rodwell et al., 1976) and is further regulated by
oxysterols (in particular 25HC) through proteasomal degradation
elicited by INSIG1. In addition, 25HC may also regulate choles-
terol homeostasis through its ability to activate liver X receptors
(LXR) and a variety of other isoprenoid and sterol metabolic inter-
mediates can negatively feedback on sterol biosynthesis (Es-
penshade and Hughes, 2007; Song et al., 2005).
Viruses are known to alter cellular lipid metabolism to facilitate
their ownmultiplication and, importantly, inhibition of cholesterol
and fatty acid biosynthetic pathways has been shown to curtail
virus replication, maturation and secretion (Clark et al., 2012;
del Real et al., 2004; Munger et al., 2008; Pen˜a and Harris,
2012; Potena et al., 2004; Spencer et al., 2011; Taylor et al.,
2011; Ye et al., 2003; Yu et al., 2012). In this regard, interferon
(IFN)-mediated downregulation of the sterol biosynthesis path-
way has been shown to be an integral part of Mf host defense
(Blanc et al., 2011; Watterson et al., 2012). It is well recognized
that IFNs, in particular type I, play a pivotal role in inhibiting viral
growth through the activation of IFN-stimulated genes (ISGs).
However, the specific functions of many ISGs and the mecha-
nisms by which they restrict viral replication are not well defined
(O’Neill and Bowie, 2010). The notion that there is an intrinsic
connection between the sterol network and IFN is further sup-
ported by studies showing IFN modulation of the cholesterol
Figure 1. 25HC Synthesis and Secretion by
Mf after Interferon Treatment or MCMV
Infection
(A) Work-flow for the LC-MS(MSn) analysis of
oxysterols. Quantification was performed from
reconstructed ion chromatograms by reference to
deuterated internal standards.
(B) Structure of cholesterol, the scaffold on which
oxysterols are built.
(C) Intracellular levels of oxysterols in BMDM
followingMCMV infection (MOI = 1), Ifn-g (25 U/ml)
or Ifn-b (25 U/ml) stimulation for 12 hr. A mock
sample of BMDM without stimulation or infection
was similarly analyzed.
(D) Analysis of oxysterols secreted by cells into
medium when treated as in (C). n = 3, data are
mean ± SEM.
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Coupling 25HC to IFN Antiviral Response via Stat1hydroxylase gene, Ch25h (Bauman et al., 2009; Diczfalusy et al.,
2009; Park and Scott, 2010). Importantly, however, the precise
mechanisms and physiological roles by which IFN regulates
the sterol metabolic network remain unclear.
Here, we have undertaken a comprehensive, unbiased investi-
gation of the biological role of oxysterols produced byMf during
infection and upon IFN stimulation. We provide evidence for a
biological role for 25HC as a lipid effector of the innate immune
response, highlighting the targeting of host metabolic regulatory
networks during viral infections and,more broadly, inflammation.
RESULTS
Quantitative Oxysterol Profiling of Infected or
Interferon-Activated Primary Macrophages
We speculated that the synthesis of oxysterols might have a role
in the negative regulation of sterol biosynthesis upon infection
(Blanc et al., 2011). Accordingly, we performed a comprehensive
quantitative determination of all known naturally occurring side-
chain and steroid-ring oxysterol metabolites that are produced
and/or secreted by either infected or interferon (b or g) stimulated
primary Mf (Figures 1A, 1C, and 1D). Bone-marrow-derived
macrophages (BMDMs) were infected (mouse cytomegalovirus,
MCMV) or stimulated (Ifn-b or Ifn-g) for 12 hr and the oxysterol
content of cells andmediummeasured by LC-MS(MSn) following
derivatization (see Figure 1A for workflow schematic). By gener-
ating reconstructed ion chromatograms (RICs) for mono- andImmunity 38, 106–118dihydroxycholesterols, epoxycholester-
ols, and mono- and dihydroxycholeste-
noic acids (see Figure 1B for chemical
structure), essentially all naturally occur-
ringoxysterols and their immediatedown-
streammetaboliteswereprofiled. Figure1
shows the list for common oxysterols
and those oxysterols not shown were
inclusive for 3b-hydroxycholest-5-en-22-
one, cholest-5-ene-3b,4b-diol, cholest-4-
ene-3b,6a -diol, cholest-4-ene-3b,6b –diol,
cholest-5-en-3b, 19-diol, cholest-5-ene-
3b,22S-diol, cholest-5-ene-3b,24R-diol,
cholest-5-ene-3b,7b,25-triol, cholest-(25R)-5-ene-3b,7b,26-triol, cholest-5-ene-3b,24,25-triol, 3b-hydroxy-
cholest-(25S)-5-en-27-oic acid.
The results of this oxysterol-metabolome and secretome
screen are summarized in Figure 1C (intracellular) and 1D
(secreted). Interestingly, in this study noticeable amounts of
25HC were found in unstimulated Mf but not media—a result
that perhaps reflects a pre-existing subprimed activation of Mf
(Kropp et al., 2011). Strikingly, amounts of only 25HC were mark-
edly increased by infection or treatment withMCMV or Ifn (b or g),
respectively (Figures 1C and 1D). In this study, the only other
detectable oxysterols (with systemic names provided in brackets)
were 24(S),25-epoxycholesterol (24S,25-epoxycholest-5-en-
3b-ol), 3b,7a-dihydroxycholestenoic (3b,7a-dihydroxycholest-
[25R]-5-en-26-oic) acid and 7a,25-dihydroxycholesterol (choles-
ten-5-en-3b,7a,25-diol) but at extremely low levels. Because
LC-MS(MSn) assays are exceptionally sensitive and these prod-
ucts were detected in the media only, it is possible that they
were generated by auto-oxidation. Notably, no other oxysterol
or downstream 3-oxo-4-ene metabolites of the listed oxysterols
were found. Similarly, we found no evidence for oxysterol mono-
or disulphates. The sulphation of oxysterols is known to catabol-
ically inactivate oxysterol activity and also generate alternative-
biologically active products. However, we find no detectable
presence of either the 3- or 25-monosulphate or 3,25-disulphate.
To avoid potential issues relating to serum-derived lipid
contamination, we proceeded to investigate the production of
25HC using lipid-depleted media. Time course experiments, January 24, 2013 ª2013 Elsevier Inc. 107
Figure 2. Temporal Analyses of Ch25h
Synthesis and 25HC Production
(A) Levels of secreted (A) and cellular (B) 25HC and
cellular cholesterol (C) with Ifn-b (25 U/ml) or Ifn-g
(25 U/ml) in delipidized media. n = 3, mean ± SEM.
(D) Expression level of Ch25h, Cyp27a1, and
Cyp7a1 from microarray time course experiment
in WT BMDM following MCMV infection (MOI = 1)
or Ifn-g (10 U/ml) stimulation (Cyp46a and Cyp7b1
did not reach the threshold of expression).
(E) Ch25h expression BMDM following MCMV
infection (MOI = 1) or Ifn-g (10 U/ml) stimulation.
(F) 25HC level in BMDM 24 hr following MCMV
infection, Ifn-b (10 U/ml), Ifn-g (10 U/ml) or PolyI:C
(10 ng/ml) with the mean ± SEM for data obtained
from three independent biological replicates.
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Coupling 25HC to IFN Antiviral Response via Stat1revealed that the majority of 25HC was secreted during the first
8 hr of incubation, and levels continued to rise more gradually
until the 24 hr endpoint (Figures 2A and 2B). As previously re-
ported for cells grown in normal media, a steady and significant
fall in free cholesterol, and its direct precursor desmosterol, was
observed with time suggesting a reduced biosynthetic output
(Figure 2C; data not shown) (Watterson et al., 2012). In summary,
the LC-MS(MSn) experiments revealed 25HC as the only oxy-
sterol notably upregulated following macrophage infection or
activation by IFNs. This occurred during the first hours after108 Immunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc.infection or treatment before overall
levels of cholesterol in treated cells fell
notably below those of the control.
Figures 2D and 2E show data that
suggests that the highly-specific increase
in 25HC was attributable to upregulated
expression of the hydroxylase Ch25h;
levels of the only other expressed hydrox-
ylases Cyp27a and Cyp7a that are also
implicated in 25HC metabolism were
unaltered. When a different perspective
on this result was sought and interferon
or polyI:C was used to stimulate BMDMs,
increased levels of secreted 25HC were
clearly detectable 4 hr after treatment.
PolyI:C is a potent Tlr3 agonist that stim-
ulates high levels of Ifn-b production (Fig-
ure 2F). Notably, in contrast to the
observed decline in Ch25h transcript ex-
pression, levels of secreted 25HCmetab-
olite levels remained relatively high until
24 hr in these experiments. We conclude
from the above data that interferon acti-
vation or MCMV infection of Mf results
in a large and highly focused production
of intracellular and secreted 25HC.
Exogenous Treatment and
Endogenous Secretion of 25HC by
BMDM Has Broad Antiviral Potency
It is possible that 25HC might function as
an antiviral mediator in the IFN-regulatedsterol metabolic network (Blanc et al., 2011). To test this idea, we
sought to address whether physiologically relevant concentra-
tions of 25HC, secreted by activated Mf, are capable of confer-
ring an antiviral state. We first determined in dose-response
experiments the inhibitory concentrations (IC) for viral growth
of MCMV in normal serum (i.e., sterol-replete media would favor
restricted Srebp2 processing). Figure 3A shows that under these
conditions 25HC has an IC10 of approximately 0.1 mM and an
IC50 of 2 mM and did not induce a cytotoxic effect (see Figure S1
available online). Because this level of inhibition is greater than
Figure 3. Analysis of 25HC Anti-Viral Effects, See Also Figure S1
Virus replication was monitored (A, B, D, E, and F) as a function of kinetic GFP fluorescence. Replication slopes over the linear phase were calculated and
normalized to vehicle treated cells, and themean replication slope from independent experiments calculated. For (C) Influenza virus, supernatant was collected at
16 hpi for analysis of viral titer by plaque assay. Data are mean ± SEM (three replicates).
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Coupling 25HC to IFN Antiviral Response via Stat1the known levels of 25HC that are sufficient to disrupt Srebp
processing (Radhakrishnan et al., 2007), we infer from these
experiments that in sterol-replete conditions 25HC is unlikely
to involve the Srebp processing pathway for maximal antiviral
activity (Adams et al., 2004; Yabe et al., 2002).Because cells grown under lipid-deficient media conditions
have an increased dependency on sterol biosynthesis, we also
evaluated the antiviral effect of 25HC under lipid-depleted condi-
tions (Sun et al., 2007). As shown in Figures 3A and 3B, there is
an increase in sensitivity of MCMV to inhibition by 25HC underImmunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc. 109
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Coupling 25HC to IFN Antiviral Response via Stat1these conditions. This antiviral effect is specific to 25HCbecause
other related enzymatically generated oxysterols, 19-HC and
7a-HC, fail to repress viral infection (Figure 3B). These oxysterols
are known not to inhibit the Srebp-pathway (Radhakrishnan
et al., 2007). In contrast, other oxysterols known to inhibit the
Srebp-pathway through INSIG, such as 27-HC and 24(S), 25 ep-
oxycholesterol, are similarly capable of inhibiting MCMV growth
(Figure S1B). These observations point to the possibility that
although the Srebp pathway is not absolutely essential for
mediating the antiviral effects of 25HC, it might contribute
toward enhancing the sensitivity to 25HC inhibition. The physio-
logical relevance for the lipid dependency is presently unclear.
The differential sensitivities under sterol-replete and -depleted
conditions raise the possibility for multiple levels of control. To
determine whether the differential modes of inhibition by 25HC
are specific toMCMV or whether it might have a broader antiviral
role, we next evaluated, in normal or lipid-depleted conditions,
its potency to inhibit a range of other viruses in different cell
systems. Figures 3C–3F show the quantitative determination of
the dose-dependent potency of 25HC to inhibit Influenza A
(H1N1), herpes simplex virus-1 (HSV-1), varicellar zoster virus
(VZV) and murine gamma herpes virus 68 (MHV-68) viral infec-
tions in MDCK, HeLa, MeWo, and BHK cells, respectively. The
results of these titration experiments clearly show a broad and
highly potent (IC50 values ranging from 20 nM to 750 nM) antiviral
role of 25HC (Figures 3D–3F). This effect is selective because
Figure S1C shows that under the conditions tested, 25HC
does not specifically inhibit Adenovirus 5 or 19a. We conclude
that 25HC has a high potency to inhibit a broad spectrum of
viruses from high to low physiological concentrations depending
on lipid conditions and virus-host cell system.
The pharmacologic agent LY295427 (3a,4a,5a)-4-(2-prope-
nylcholestan-3-ol) is a known antagonist of 25HC, whereas
LY306039, the 3b-isomer of LY295427, fails to derepress the
effect of 25HC (Janowski et al., 2001). We used these agents
to test whether they have any efficacy in interfering with the anti-
viral activity mediated by 25HC. Figure 4A shows the ability of
exogenous 25HC to potently inhibit viral growth and that the
observed antiviral effect can be completely blocked in the pres-
ence of LY295427 but not LY306039. These results validated our
subsequent use of LY295427 in interfering with endogenously
secreted 25HC. Accordingly, conditioned media (10 hr post-
treatment) from mock-treated, infected, Ifn-b, or Ifng-treated
Mf was incubated with vehicle alone, or with LY295427 or
LY306039 and then applied to MCMV-infected NIH 3T3 cells.
As expected, mock-conditioned media failed to inhibit viral
growth and drug treatment had no effect (Figure 4B). Meanwhile,
conditioned media from infected or IFN-treated cells had pro-
nounced antiviral activity. In the presence of LY295427, antiviral
activity was partially blocked (Figure 4B). We interpret the results
of these experiments to show that endogenously secreted 25HC
has a potent antiviral activity and, if we assume, LY295427 is an
exclusive inhibitor of 25HC, this accounts for at least 40%–50%
of the antiviral secretome activity. It is likely that the secretion of
other antiviral cytokines rather than an incomplete blockade
provides the remaining antiviral activity. Overall, these experi-
ments demonstrate that Mf activated Ch25h generates biolog-
ical antiviral activity through paracrine, and in the case of Mf
also autocrine effects of 25HC.110 Immunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc.25HC Antiviral Actions Are LXR Independent and
Enantioselective
The above studies raise the possibility for potentially direct
and indirect modes of 25HC action. It is conceivable that
inhibitory effects of 25HC above 0.5 mMmight involve an indirect
membrane-mediated mechanism, whereas those below 0.5 mM
may have a direct protein mediated mode of action. It is also
plausible that 25HC could be metabolized to a more potent anti-
viral metabolite. A candidate pathway is the Epstein-Barr virus-
induced gene 2 (EBI2/GPR183) enzyme system (Hannedouche
et al., 2011; Liu et al., 2011). The natural ligand for EBI2 has
been identified as 7a,25-diHC. In this pathway, a critical enzyme
required for the generation of 7a,25-diHC is CH25H, however, in
our mouse experiments Ebi2 gene expression is downregulated
in Mf upon productive and nonproductive infection as well as
polyI:C treatment, in an IFN-dependent manner (Figure 4C), sug-
gesting that it is unlikely to be involved in the antiviral response.
Intriguingly, the coordinated IFN suppression of the Ebi2 medi-
ated 25HC-catabolic-pathway further underscores the highly
focused 25HCMf response and is unlikely to involve an interme-
diary metabolite mode of action.
To evaluate generalized membrane effects and further test the
specificity of 25HC actions, we studied the activity of ent-25HC,
an enantiomer of 25HC. In these experiments, we assumed the
well-known ability of 25HC to interact and change the properties
of cellular membranes would be enantiomer insensitive while
protein specific inhibitory effects on viral growth would be
restricted to 25HC. Figure 4D shows that ent-25HC has antiviral
activity but only at concentrations exceeding 1 mM, which is
below the nonselective effects of oxysterols on viral infection
and is an order of magnitude less potent at inhibiting MCMV
than 25HC (Figure 4D). These results show that the effect of
25HC on antiviral activity is highly enantio-selective, consistent
with the idea that 25HC antiviral functions occurs through
a specific protein target(s). Because ent-25HC can exert an anti-
viral effect at high concentrations it is likely that this activity
occurs via an indirect mode of action mediated at the membrane
level. Notably, the antiviral effect of ent-25HC provides evidence
for Srebp-independent antiviral pathway that might act as a
cofactor for membrane proteins or acting as a determinant for
membrane lipid composition or compartmentalization (Contre-
ras et al., 2012).
In the case of lipid-depleted conditions, our data is consistent
with a subordinate inhibition of the Srebp pathway by 25HC and
by other oxysterols such as 24S, 25-epoxycholesterol or 27-HC.
Notably, these oxysterols are also known to activate LXR
(Janowski et al., 2001). Thus, we next evaluated the transcrip-
tional responses of LXR and Srebp target genes in Ifng-treated
or MCMV-infected Mf. In these experiments, molecular profiling
of Ifng andMCMV infectedMf every 30min for 12 hr showed the
expected downregulation of Srebp2 target messenger RNAs
(mRNAs) including Insig1 (Figure 4E). However, the temporal
dynamic changes were complex. In this analysis, increased ex-
pression of Ch25hmRNA levels is associated with a subsequent
activation of the LXR target genes Mylip and Abcg1. To directly
test whether LXR ligand activation is sufficient to develop an anti-
viral state, we treated MCMV infected cells with 1 mM of the
potent synthetic LXR ligands (GW3965 and T0901317). Although
these ligands were active in LXR-dependent reporter assays
Figure 4. Investigation of Specificity and
Selectivity of 25HC Antiviral Activity, See
Also Figure S2
(A) NIH 3T3 cells were infected with MCMV-GFP
virus (MOI = 0.05) treated with 25HC in the pres-
ence or absence of Ly295427 (20 mM) or Ly306039
(20 mM). The level of infection was measured by
determining the GFP fluorescence level after 72 hr
infection. n = 3, data are mean ± SEM (three
replicates per experiment).
(B) NIH 3T3 cells infected with MCMV-GFP virus
(MOI = 0.05) received conditioned medium from
BMDM infected, or treated with IFN-b (25 U/ml) or
IFN-g (10 U/ml) ± 20 mM Ly295427 or 20 mM
Ly306039. n = 3, and data are mean ± SEM (with
three biological replicates per experiment).
(C) Expression analysis of Gpr183 (relative to t = 0)
in WT, Ifnb/ or Ifnar1/ BMDM infected with
MCMV or MCMVdie3 (MOI = 1) or treated with
PolyI:C (10 ng/ml). Each column represents one
time point and row represents one gene. Gene
expression is shown as a pseudocolor – blue =
decrease, yellow = increase. Log fold change
values were calculated by subtracting the t =
0 signal value from the signal value at time points
after infection or treatment.
(D) MEF were pretreated with 25HC or ent-25HC
in delipidized medium for 24 hr and infected
with MCMV-GFP (MOI = 1). n = 2, data are mean ±
SEM (with three biological replicates per experi-
ment).
(E) BMDM treated with 10 U/ml Ifn-g or mock-
treated (F). Heatmap showing temporal alterations
in abundance of sterol-related transcripts in Ifn-g-
treated BMDM (E, relative to t = 0) or MCMV
infected BMDM (F, relative to t = 0) as in (C).
(G) NIH 3T3 cells were pretreated with GW3965
(1 mM), T0901317 (1 mM) or 25HC (10 mM) in normal
or delipidized medium for 24 hr and then infected
with MCMV-GFP. After infection, all wells received
fresh medium containing normal or delipidized
serum and GW3975, T0901317, or 25HC. Data
are normalized to negative controls treated with
vehicle alone and are the mean of six independent
experiments ± SEM (three biological replicates per
experiment).
(H) MEFs were pretreated with GW3965 (1 mM),
T0901317 (1 mM) or 25HC (10 mM) in normal or
delipidized medium for 24 hr and then infected
with MCMV-GFP as described in (G). Data are
normalized to negative controls treated with
vehicle alone and are the mean of six indepen-
dent experiments ± SEM (three replicates per
experiment).
(I) Left shows MEFs infected with MCMV (MOI = 0.1) incubated with 25HC (1 mM) and/or GGOH (20 mM) or MEV (20 mM) and MCMV titer determined by plaque
assay. Data are mean of three independent experiments ± SEM. *p% 0.05. Right shows that MEFs infected with MCMV (MOI = 0.1) were incubated with vehicle,
25HC – (1 mM), and/ or Farnesol (FOH – 20 mM) or Squalene (Sqle – 20 mM) and MCMV titer was determined by plaque assay. Data are the mean of two inde-
pendent experiments.
(J) RISC-Free, Fnta, Fntb, Pggt1b, Rabggta, Rabggtb, or MCMVM54 siRNA (25nM) were reverse-transfected into NIH/3T3 cells. Forty-eight hr after transfection,
cells were infected with MCMV-GFP (MOI = 0.05) and virus replication monitored. Data are normalized to RISC-free wells and are mean of six independent
experiments ± SEM.*p < 0.05, **p < 0.01, *** < 0.001.
(K) Left shows that MEF were pretreated with 25HC (5 mM) or psoromic acid (20 mM) for 24 hr, infected with MCMV-GFP (MOI = 0.05), and then incubated with
EMEMwith the same concentrations of 25HC or psoromic acid. Data are normalized to vehicle treated wells and aremean of two independent experiments. Right
shows that MEFs were pretreated with vehicle, FTI-277 (10 mM), or GGTI-2133 (10 mM) for 24 hr, infected with MCMV-GFP (MOI = 0.05), and incubated with the
same concentrations of FTI-277 or GGTI-2133 as prior to infection. Data are normalized to vehicle treated wells and are mean of two independent experiments
with three biological replicas (error bars represent range).
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Figure 5. Analysis of 25HC Effects on Cell Death, Virus Entry and Cell-to-Cell Spread, See Also Figure S3 and Movie S1
(A) Left shows NIH 3T3 cells treated with 25HC in delipidized medium andMCMV infected (MOI = 2). Three hpi DNA levels were determined by qRT-PCR. Middle
shows RAW 264.7 cells treated with 25HC (5 mM) pre- or postinfection with MCMV (MOI = 1) in normal medium. At 3 hpi, amounts of internalized viral DNA were
(legend continued on next page)
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Coupling 25HC to IFN Antiviral Response via Stat1(Figure S2A), they failed to elicit an antiviral response and, there-
fore, we conclude that LXR activation is insufficient to affect viral
inhibition of MCMV in both normal or lipid depleted media condi-
tions (Figures 4G and 4H; Figures S2B and S2C).
25HC Antiviral Action Partially Involves the Mevalonate
Branch, Blocking Postentry Viral Growth
A decrease in the Srebp2 target genes of the sterol pathway and
especially the mevalonate-isoprenoid side branch is notable (in
particular Mvd and Fdps) (Figures 4E and 4F). Mevalonate is
a shared precursor of coenzyme Q, ubiquinone, dolichol, farne-
syl, and geranylgeranyl pyrophosphates. The latter two isopre-
noids are necessary for protein prenylation. Many viruses require
prenylation of essential viral or host proteins (e.g., the large delta
antigen of HDV or the pseudorabies virus tegument protein) (Bor-
dier et al., 2003; Clase et al., 2003) or (e.g., host protein FBL2 for
hepatitis C virus [HCV] or RhoA activation for RSV) (Ye et al.,
2003) (Wang et al., 2005) (Gower and Graham, 2001). In the
case of MCMV, we find, upon inhibition of the prenyltransferase
branch by RNAi, that viral replication is selectively reduced upon
knockdown of GGTase II but not GGTase I or farnesyltransferase
(Figure 4J), confirming previouswork defining the dependency of
MCMV for the isoprenoid pathway (Blanc et al., 2011). In the
present study, Rabggta and Rabggtb small interfering RNA
(siRNA) reduced the abundance of their target transcript by
around 60% (Figure S4F) and none of the above siRNA signifi-
cantly reduced cell viability (Figure S4D). To investigate whether
25HC antiviral functions involve the mevalonate branch, we
treated MCMV infected cells with nonsaturating inhibitory levels
of 25HC (<1 mM) and coincubated with mevalonolactone (MEV),
geranylgeraniol (GGOH), or Farnesol (FOH), and the amount of
infectious virus determined. In these metabolic rescue experi-determined by qRT-PCR. Right shows MEFs treated with 25HC (5 mM) 24 hr prior
virus titers determined by plaque assay 4 dpi. n = 4, with mean ± SEM. ***p% 0
(B) NIH 3T3 cells were treated with 10 mM 25HC or 10 mM staurosporine in norm
(C) Left shows images of NIH 3T3 cells with and without 25HC 2.5 mM infected w
media. Images of NIH 3T3 cells infected with MHV-68 39 hpi. Right shows HeLa
normal medium and images taken 24 hpi.
(D) NIH 3T3 cells infected with MCMV (MOI = 0.005) and treated with 0.1, 1, or 5
(E) p53/ MEFs were infected with MCMV-GFP (MOI = 0.001) and overlaid in no
diameter was measured 3 dpi. Data are mean 170 and 220 plaques counted ± S
(F) H1N1: Plaque reduction assay of Influenza A/WSN/33 (H1N1) virus infection of
overlay. Forty-eight hpi, cells were stained with 0.1% toluidine blue and number a
representative images showing differences in plaque size and morphology. Right
(lower, mm2) per well. HSV-1-eGFP (C12) infection of A549 cells pretreated wit
diameters were determined 72 hpi. cell. Representative fluorescent microscopic
are shown. Plaque numbers (top right) and mean plaque diameter (bottom right)
**p% 0.01.
(G) Left shows that NIH 3T3 cells were infected with MCMV (MOI = 2.5) in de
(extracellular virus) and intracellular virus quantitated by plaque assay. n = 4, mean
influenza virus (MOI = 1), serum-freemedium containing vehicle, or 25HC (2.5mM),
fixed and stained. n = 4 mean ± SEM. ***p% 0.001.
(H) Left shows plaque diameters observed in experiment and predicted by mode
Right shows that plaque diameters observed in experiment and predicted by m
between cells in a dose-dependent manner.
(I) MEFs pretreated with 25HC (5 mM) for 24 hr, infected with MCMV (MOI = 0.3),
(J) Left shows that BMDMwere pretreated with Ifn-g (10 U/ml) or 25HC (5 mM) for 2
measured using supernatants. n = 6 ± SEM. Right shows that RAW264.7 cells we
(MOI = 2), in normal medium containing vehicle, IFN-g (10 U/ml) or 25HC (2 mM) for
SEM. *p% 0.05.ments, viral growth was restored with MEV or GGOH but not
FOH (Figure 4I). However, in the presence of saturating inhibitory
concentrations of 25HC (>5 mM), viral growth is not recovered
with MEV, GGOH, or FOH cotreatment (data not shown) indi-
cating that under these conditions the isoprenoid-prenylation
arm is not required. It is possible that other derivatives such as
dolichol may be required. Altogether, these investigations are
indicative that for MCMV, 25HC blocking of the mevalonate
branch imparts a contributory role but is not absolutely essential.
As expected, inhibitors of GGTase I (GGTT-2133) or farnesyl-
transferases (FTI-277) fail to inhibit MCMV, whereas psoromic
acid (an inhibitor of GGTase II [Deraeve et al., 2012]) restricts viral
growth (Figure 4K). None of these compounds significantly
affected cell viability (Figure S2E).
We next investigated at what stage in infection 25HC blocks
MCMV growth. The results shown in Figure 5A indicate that
the level of internalized MCMV genomes is unaffected by
25HC. Furthermore, in plaque reduction assays the number of
primary infectious foci is equivalent in the presence or absence
of 25HC (Figure 5E). These results argue against viral entry as
a primary mode for MCMV inhibition. In this connection, we
also find that 25HC is highly effective at blocking (at 40 nM inhib-
itory concentration) VZV infection of MeWo cells (Figure 3E). This
represents an infection model in which cell-free virus is not pro-
duced and the infection process is exclusively dependent on
cell-cell spread. 25HC at high concentrations has been shown
to promote apoptosis, a well-characterized antiviral mechanism,
in a range of cell types including Mf (Rusin˜ol et al., 2004).
Notably, however, as shown for NIH 3T3 cells (Figure 5B),
25HC at high antiviral concentrations (10 mM) fails to significantly
induce cellular apoptosis in comparison with staurosporine.
Again, we cannot rule out that other cell-virus systems mayto and after infection with MCMV (MOI = 2.5) in delipidized media and infected
.001.
al media and cell death measured. Data are mean ± SEM for three replicates.
ith MCMV (MOI 0.01). Middle shows cells treated with 2.5 mM 25HC in normal
cells infected with HSV-1 VP26-YFP (MOI = 3), treated with 25HC (20 mM) in
mM 25HC in normal media. Images were taken at 72 hpi.
rmal medium containing 2.5% agarose and 0.1, 1, 2.5, or 5 mM 25HC. Plaque
EM (three biological replicates). *p% 0.05, **p% 0.01.
MDCK cells in the presence or absence of 25HC (2.5 mM) and a 0.5% agarose
nd size of plaques determined. Left upper (vehicle) and lower (25HC) panels are
panels show mean number of plaques per well (upper) and mean plaque area
h vehicle or 25HC (5 mM) with a 0.5% agarose overlay. Plaque numbers and
images of plaques from vehicle- (top left) or 25HC- (bottom left) treated cells
from HSV-1 infected cells are shown. n = 6, data are mean ± SEM. *p% 0.05,
lipidized medium containing vehicle or 25HC (5 mM). Two dpi supernatants
± SEM. ***p% 0.001. Right showsMDCK cells infected with A/WSN/33 (H1N1)
and 0.5%agarosewas added to themonolayers. After 16 hpi, monolayerswere
ling when cell permissivity and viral growth both mediate 25HC antiviral effect.
odeling when only cell permissivity contributes to the infectious transmission
and DNA levels quantitated at indicated times.
4 hr, infected with GLucMCMV and at 2 or 4 hpi and Gaussia luciferase activity
re pretreated for 24 hr with Ifn-g (10 U/ml) or 25HC (2 mM), infected with MCMV
24 hr, relative abundance of theMCMV ie1 assayed by qRT-PCR. n = 3;mean ±
Immunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc. 113
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Coupling 25HC to IFN Antiviral Response via Stat1employ a 25HC mediated apoptotic antiviral response. In this
regard, we have found BMDM to be especially sensitive to
25HC concentrations above 2 mM.
We notedmarked inhibitory effects on plaque development for
all viruses investigated (Figure 5C–5G). Dose response analyses
of MCMV plaque formation clearly indicated that the ability of the
virus to spread decreased with increasing dose of 25HC (Figures
5C and 5D), while no statistical differences in numbers of infec-
tion foci in the presence or absence of 25HC were obtained (Fig-
ure 5E). In plaque reduction assays a significant dose-dependent
difference in the diameter of the viral plaque was observed (Fig-
ure 5E). Similar results were also obtained from plaque reduction
assays for influenza virus (Figure 5F). A simple mathematical
model that best fits the experimental data is the one in which
growth dominates over susceptibility to infection (Figure 5H; Fig-
ure S3F; Movie S1). In agreement, single hit growth analyses
of MCMV and influenza infection show that 25HC effectively
inhibits viral growth (Figure 5G) and for MCMV, 25HC inhibits
yields of intracellular and secreted virus to the same extent (Fig-
ure 5G). However, in the case of HSV-1we observed a significant
difference in both plaque size and number of plaques (Figure 5F;
Figure S3E) suggesting viral entry and growth can be affected
and further indicating the multiple levels of control exerted by
25HC depending on the virus-host cell system.
In accordance with the above results we observed a reduction
at the level of viral DNA replication by 25HC (Figure 5I). This is
associated with reduced amounts of early (E1) and late (M115)
gene expression in a 25HC dose-dependent manner strongly
supporting a postentry stage inhibition of MCMV infection
(Figure S3A). For MCMV Mf infection, IFNs mediate antiviral
effects through inhibition of the major immediate-early promoter
(MIEP) (Kropp et al., 2011). We also find that 25HC imparts, in
a dose dependent manner, inhibition of the MIEP monitored
by using either reporter virus assay or the endogenous ie1
expression levels, resulting in approximately 50% inhibitory
activity in comparison with Ifng treatment (Figure 5J; Figures
S3B and S3C).
Interferon Stimulation of 25HC Production Involves
Direct Binding of Stat1 to Ch25h Promoter
A central question regarding the role of 25HC in terms of innate
immunity is how IFN signaling precisely regulates Ch25h. Thus,
in our next experiments we sought to investigate in further detail
the regulatory interferon dependence of the 25HC responses by
using host and viral genetic knockouts in our macrophage-infec-
tion experiments. First we assessed whether the IFN-b plays
a role in mediating the induction 25HC in infection. Figure 6A
shows that greater than 80% of the induction response of
Ch25h is lost in Ifnb1/ Mf, whereas 100% of the response is
eliminated in Ifnar1/Mf. Because all type I IFNs signal through
the Ifnar1 receptor, these results indicate that upon infection of
Mf, Ifn-b is the primary mediator, whereas other members of
the type 1 interferon family serve a minor nonredundant role.
To determine whether a productive infection is required,
we used a mutant virus (MCMVdie3) that is fully proficient in in-
fecting cells but fails to initiate viral gene expression. In the
following experiments, infection of Mf with MCMVdie3 resulted
in an equal response of Ch25h activation in comparison with
the parental wild-type (WT) virus but with slightly delayed114 Immunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc.temporal kinetics (Figure 6B). In this case, and in comparison
with Ifnar1/-infected cells, Ifn-b dominates the response (Fig-
ure 6B). These results show that productive infection is not
required; indicating that pattern recognition receptor activation
by the viral particle is sufficient to activate the transcriptional
induction of Ch25h.
In our Mf cultures, Ifn-g is not expressed but, as shown in Fig-
ure 1, is a potent inducer of Ch25h activity. Figure 6C shows that
infection or treatment with exogenous Ifn-b of Ifnar1/Mf abol-
ishes the induced levels of 25HC, whereas exogenous Ifn-g
treatment does not. Because signal transducer and activator of
transcription factor 1 (Stat1) is activated by Ifn-g though its
receptor Ifngr and Stat1 and Stat2 are activated by Ifn-b through
its receptor Ifnar1, we next tested the ability of MCMV, Ifn-b and
Ifn-g to activate Ch25hmRNA levels in Stat1/ cells. Figure 6D
clearly shows that genetic elimination of Stat1 results in the
marked loss of the ability of Mf to activate Ch25h upon infection
or treatment with type 1 or type 2 IFNs.
To further investigate the kinetic transcriptional induction
of Ch25h, we quantitatively determined the de novo synthesis
of RNA using 4-thiouridine incorporation. A schematic of this
procedure is shown in Figure S4A. In these experiments,
between 60 and 90 min after treatment, de novo synthesis of
the Ch25h transcript increased by approximately 30-fold in
Ifn-g treated cells relative to the mock sample (Figure 6E). To
test whether signaling from Ifnar1 was necessary for the in-
duction of Ch25h during viral infection, we next conducted de
novo synthesis experiments in Tyk2/ macrophage cells. The
results shown in Figure 6F indicate that direct signaling by the
receptor rather than an indirect or secondary mode of activa-
tion is crucial in virus-induced Ch25h synthesis and is consistent
with the possibility of Stat1 involvement in this process. To
explore this possibility further, we next conducted a microarray
analysis of de novo transcription during the first 8 hr after
IFN-g stimulation of macrophages. An unbiased clustering anal-
ysis of temporal differential synthesis profiles identified a subset
of 51 gene transcripts kinetically related to Ch25h, including Irf1
and Tap1, (Table S1; Figure 6G). Having demonstrated a notable
increase in Ch25h transcript synthesis during the first 30 min
after IFN-g treatment, we sought to bioinformatically investigate
promoter regions for common transcription factor binding sites.
To this end, we applied a statistical analysis of transcription
factor overrepresentation in transcripts increased by >2-fold
during the first 30 min after IFN-g treatment. An analysis of
109 transcripts identified (including Ch25h) (Table S2) revealed
Stat1 as the only transcription factor identified with a combined
Z score of >10 and Fisher score of <0.01 (values defined by
empirical studies).
Because Stat1 is activated under all three conditions tested
(MCMV infection, Ifn-b and Ifn-g treatment) and multiple poten-
tial Stat1 binding sites are present upstream of Ch25h start site
(Figures S4B and S4D). We sought to directly test these predic-
tions using a chromatin immunoprecipitation (ChIP) of Stat1-
bound DNA from BMDM treated with Ifn-g for 1 hr (Figure 6I).
The ChIP analysis of Ch25h promoter proximal sequences re-
vealed an Ifn-g-mediated recruitment of Stat1 to the predicted
binding region of the Ch25h locus (Figure 6I). To extend this
analysis, a ChIP-Seq analysis of histone modifications identified
as markers of accessible and active chromatin regions, revealed
Figure 6. 25HC Synthesis Is Interferon-
Dependent and Regulated by Stat1; See
Also Figure S4 and Tables S1 and S2
(A and B)Ch25h gene expression (relative to mock
infected cells) in WT, Ifnb/ or Ifnar1/ BMDM
infected with MCMV or MCMVdIE3 (MOI = 1).
(C) Changes in intracellular 25HC in Ifnar1 KO
BMDM following MCMV infection, Ifn-b (10 U/ml)
or Ifn-g (10 U/ml) stimulation for 24 hr. n = 3; data
are mean ± SD.
(D) qRT-PCR analysis of Ch25hmRNA expression
at 6 and 24 hpi with MCMV (MOI = 1) or treatment
with Ifn-g (10 U/ml) or Ifn-b (25 U/ml) in WT,
Ifnar1/ or Stat1/ BMDM. n = 3, data are
mean ± SD.
(E) Differential ntRNA synthesis between 60 and
90 min in Ifn-g treated (F) or MCMV-infected
BMDM (H) relative to mock were analyzed and
fold-change values in treated or infected cells
calculated relative to the control.
(G) WT BMDM treated with Ifn-g (10 U/ml).
Microarray analysis of newly transcribed RNA
isolated from 16 successive 30 min windows after
treatment.
(H) UCSC genome browser image is shown for
Ch25h locus indicating Stat1 binding site (labeled
ch25h_8) in promoter region. Normalized tag
counts for H3K4me2-MNase ChIP-Seq, H4K5Ac-
ChIP-Seq, and H3K4me3-ChIP-Seq are shown for
untreated BMDM.
(I) ChIP analysis of Stat1 binding at Igk (negative
control), Tap1, and Nos2 (positive controls), and
Ch25h loci (as indicated in Figure 5I) in mock-
or Ifn-g (20 U/ml, 1 hr) treated BMDMs. Fold
enrichment for each locus is the ratio of
percentage input of Ifn-g-treated versus mock-
treated BMDMs. IgK (negative control) refers to
genomic region lacking Stat1 enrichment. Data
are representative of two independent experi-
ments performed in duplicate.
Immunity
Coupling 25HC to IFN Antiviral Response via Stat1that, in BMDM, the Stat1 binding occurs within a region charac-
terized by these active signatures (Figure 6H). Collectively,
these experiments show that Ch25h transcriptional activation
is coupled to the interferon response through a direct molecular
link with Stat1.
DISCUSSION
The innate immune response and the homeostatic pathways
controlling cellular sterol levels are now known to regulate
each other reciprocally (Castrillo et al., 2003; Kwak et al., 2000;Immunity 38, 106–118Weitz-Schmidt et al., 2001). Our present
findings demonstrate that Mf have
evolved a program by which IFN is
directly coupled to the regulation of
25HC. Although 25HC is a well-known
negative feedback mediator of the sterol
pathway, we present evidence that it
can mediate, at multiple levels, antiviral
cellular functions. We show that the
mechanism for this coupling is throughthe direct recruitment of Stat1 to the promoter proximal region
of the Ch25h gene. Strikingly, a comprehensive metabolome
profiling of oxysterols shows that the classical activated Mf
response is highly focused toward a single oxysterol, 25HC.
We find that 25HC can impart antiviral cellular functions via an
LXR-independent but Srebp-dependent subordinate mecha-
nism, highlighting a previously unrecognized biological role for
25HC as part of the innate-immune response.
The subordinate involvement of the Srebp pathway for 25HC
antiviral activity is based on the following: (1) In normal
media, under conditions that reduce the cells reliance on the, January 24, 2013 ª2013 Elsevier Inc. 115
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Coupling 25HC to IFN Antiviral Response via Stat1Srebp-processing pathway, IC50 values obtained are far higher
than the known IC50 for 25HC inhibition of Srebp processing.
(2) An enantiomer of 25HC inhibits viral infection; however, this
only occurs at concentrations above 1 mM. We infer from this
a Srebp-independent mode of action. (3) The antiviral potency
of 25HC viral is dramatically increased for most, but not all, infec-
tions under lipid-depleted conditions that favor Srebp process-
ing. Under these conditions, IC50 values for 25HC approximate
those that actively inhibit the Srebp-pathway. (4) Oxysterols
known to target the Srebp-pathway can effectively inhibit viral
growth in lipid-depleted conditions, whereas those that do not
regulate Srebp fail to affect viral growth. Future studies will be
required to further understand the contribution of the Srebp-
dependent and independent pathways to 25HC-induced anti-
viral activity.
How IFN couples with the regulation of the sterol metabolic
network is relevant for both innate and adaptive immunity. In
recent years, several groups have defined newmechanistic links
between the sterol metabolic network and innate (Blanc et al.,
2011; Diczfalusy et al., 2009; Im et al., 2011; Liu et al., 2012; Yi
et al., 2012) or adaptive (Bauman et al., 2009; Hannedouche
et al., 2011) immune responses. Similar to IFN, 25HC is found
to halt MCMV growth in Mf cells by impeding postentry viral
gene expression. IFN is known to dramatically alter in BMDMs
both an increase and decrease in abundance of prenylated
proteins (Vestal et al., 1995). One potential pathway for blocking
MCMV growth is through altering the mevalonate (isoprenoid)
branch of the pathway. Our previous studies had indicated that
coincubation of IFN treated infected cells with GGOH partially
rescues the antiviral response (Blanc et al., 2011). It is note-
worthy that many viruses require prenylation of either viral or
host proteins for productive infection (Amet et al., 2008; Bordier
et al., 2003; Clase et al., 2003; Gower and Graham, 2001; Wang
et al., 2005; Ye et al., 2003). Whether 25HC affects protein pre-
nylation remains to be determined; however, we note that
a number of highly specific prenylation inhibitors have been
shown to significantly inhibit viral multiplication in vitro and in vivo
(Bordier et al., 2003; Glenn et al., 1992; Gower and Graham,
2001; Ye et al., 2003).
In summary, our study demonstrates a previously unrecog-
nized biological role for 25HC as an effector of the early innate-
interferon response capable of imparting antiviral intracellular
functions. Stat1 binding the Ch25h promoter provides a critical
molecular link between innate immune stimulation, infection,
and the Mf secretion of a single oxysterol, 25HC.
EXPERIMENTAL PROCEDURES
Cell Propagation and Culture
BMDM were derived from femur and tibia isolated from C57BL/6 mice and
grown in DMEM/F12 + GlutaMAX (Lonza, Vervier, Belgium) supplemented
with 10% fetal bovine serum (FCS), 10% L929 conditioned medium (contain-
ing colony-stimulating factor Csf1) and Penicillin + Streptomycin. FACs as-
sessed BMDMs for Mf cell surface markers, F480 and CD11b. All procedures
were carried out under project and personal licences approved by the Secre-
tary of State for the Home Office, under the United Kingdom’s 1986 Animals
(Scientific Procedures) Act and the Local Ethical Review Committee at
Edinburgh University. All cultures are routinely tested for mycoplasma and
endotoxin levels. Full details for these cultures and for MEFs and cell lines;
NIH 3T3, RAW264.7, 199, MDCK, HeLa, MeWo and 293 cells are provided
in the Supplemental Experimental Procedures.116 Immunity 38, 106–118, January 24, 2013 ª2013 Elsevier Inc.Reporter Viruses and Viral Plaque Assays
Viral growth including plaque assays, reporter GFP, and luciferase assays for
viral growth and gene expression measurements for WT MCMV, MCMV-GFP,
GLuc-MCMVMurineGammaherpesvirus68 (MHV-68-GFP), VZV-GFP (vaccine
strainOka),HSV-1-eGFP (C12), A/WSN/33 (H1N1) influenza virus, Ad5-gfp, and
Ad19a-gfp are described in Supplemental Experimental Procedures. Plaque
reduction assays used an agarose overlay for MCMV, HSV, and Influenza virus
infection. ForMCMVandHSV,plaquenumbersanddimensionswerequantified
using fluorescent microscopy of infection foci. Phase-contrast and fluores-
cence visualization of infected was performed using a Zeiss Axio Observer Z1
inverted microscope (Carl Zeiss, Germany). Microscope control and image
capture were undertaken using Axiovision Software (Carl Zeiss, Germany). All
images were captured and diameters quantified using ImageJ software.
Metabolic Profiling of Oxysterols
Details for the extraction of oxysterols and sterols are provided in Supple-
mental Experimental Procedures. The extracted oxysterol and sterol fractions
were derivatized withGirard P reagent and analyzed by LC-MS(MSn) on a LTQ-
Orbitrap Velos. Mass spectra were recorded at high resolution in the Orbitrap
analyzer, andMSn spectra recorded simultaneously in the LTQ ion-trap. Quan-
tification was performed by stable isotope dilution on reconstructed ion-chro-
matograms generated in the Orbitrap.
Microarray Analysis, RNA Labeling, and Isolation from BMDM
Cultures
Incorporation of 4-thiouridine (Sigma) into newly-transcribed RNA including
experiments of RNA time course microarray analysis of transcriptional
changes in WT, Ifnar/, and Ifnb1/ BMDM following MCMV infection and
quantitative RT-PCR using taqman primer probe sets (from Applied Bio-
systems) or for viral transcripts see Supplemental Experimental Procedures.
Time course microarray analysis data are compliant with the National Centre
for Biotechnology Information Gene Expression Omnibus (GEO) under
SuperSeries accession number GSE42505 (SubSeries numbers GSE42503,
GSE42504) (GEO, http://www.ncbi.nlm.nih.gov/geo/).
Statistical Analysis of Transcription Factor Binding Site
Overrepresentation
Entrez gene ID’s for 164 transcripts with a fold change of >2-fold in the Ifn-g-
treated BMDM samples between 0 and 30 min were imported into the
oPOSSUM software tool (http://www.cisreg.ca/cgi-bin/oPOSSUM/opossum)
and analyzed as described in Supplemental Experimental Procedures.
Isolation and Quantification of Viral Genome Copy Number by Using
qPCR
For DNA extraction, cells were extensively washed thrice 3 hr postinfection
and total genomic DNA isolated and genome copy number normalized to input
DNA or to gapdh using quantitative procedures described in Supplemental
Experimental Procedures.
Oxysterol Screening against MCMV, HSV-1, MHV-68, VZV, Influenza
A, and Adenovirus
For these experiments, respective host cell systems were conducted in
black 96-well plates using media conditions and oxysterol treatment as
described in the figure legends and Supplemental Experimental Procedures.
The IC50 values were calculated as the concentration at 50% viral inhibition.
Cell viability and toxicity assays were determined using the CellTiter Blue
(CTB, Promega) reagent.
Metabolite Treatment of Cells
Murine embryo fibroblasts were infected with MCMV (MOI = 0.01). After
adsorption, cells were washed 5 times with normal medium (DMEM, 10%
FCS, L-Glutamine and Penicillin/Streptomycin). After washing, normal medium
containing vehicle (Ethanol) or 25HC (1 mM) ± Geranylgeraniol (GGOH, 20 mM)
(Sigma G3278) or Mevalonolactone (Mev, 20mM) (Sigma M4667), Farnesol
(FOH, 20 mM) (Sigma F203) or Squalene (Sqle, 20 mM) (Sigma S3026) was
added to the infected wells. After 4 days, supernatants were collected and
MCMV titer calculated by plaque assay.
Immunity
Coupling 25HC to IFN Antiviral Response via Stat1Computational Prediction of Stat1 Binding Sites in the Ch25h
Promoter
To analyze and predict potential Stat1 binding sites in the promoter of Human
and Mouse Ch25h genes, we used the open source software Toucan. In brief,
1Kb 50 cis-regulatory regions upstream of the transcriptional start sites of
human (ENSG00000138135) or mouse (ENSMUSG00000050370) Ch25h
were imported into Toucan. Predicted transcription factor binding sites were
then identified in these sequences using the MotifLocator algorithm. Position
Weight Matrices for this analysis were derived from the TransFac database
V7.0 (public) and the background model used was either mouse or human
DBTSS promoters depending on input sequence. A default stringency
threshold of 0.9 was used for all predictions.
Chromatin Immunoprecipitation (ChIP)
For ChIP of Stat1, 6 3 107 Mf were used per ChIP, as detailed in the Supple-
mental Experimental Procedures, including the analysis of ChIP-Seq data for
UCSC Browser image of Ch25h locus.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, Supplemental
Experimental Procedures, and one movie and can be found with this article
online at http://dx.doi.org/10.1016/j.immuni.2012.11.004.
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